Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Hyman

Showing results (111-120 of 174) with videos related to

Pageof 18
Sort By:
Gynecologic Oncology|November 24, 2019
Clinical outcomes of patients with POLE mutated endometrioid endometrial cancerMarina Stasenko, Irina Tunnage, Charles W Ashley, et al.
Blood|August 24, 2014
Recurrent RAS and PIK3CA mutations in Erdheim-Chester diseaseJean-François Emile, Eli L Diamond, Zofia Hélias-Rodzewicz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2017
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial CarcinomaMin Yuen Teo, Richard M Bambury, Emily C Zabor, et al.
JCO Precision Oncology|September 11, 2020
Real-World Outcomes of an Automated Physician Support System for Genome-Driven OncologyJessica J Tao, Michael H Eubank, Alison M Schram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2018
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for InterventionMaeve A Lowery, Ryan Ptashkin, Emmet Jordan, et al.
Cancer Discovery|August 11, 2018
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front MutationsAlexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, et al.
Cancer|August 19, 2020
Clinical implications of drug-induced liver injury in early-phase oncology clinical trialsSebastian P Mondaca, Dazhi Liu, Jessica R Flynn, et al.
Investigational New Drugs|March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxelLillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2022
Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIEMichele L LeNoue-Newton, Sheau-Chiann Chen, Thomas Stricker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2018
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune TherapiesJames J Harding, Subhiksha Nandakumar, Joshua Armenia, et al.
Pageof 18

Showing results (111-120 of 174) with videos related to

Sort By:
Pageof 18
Gynecologic Oncology|November 24, 2019
Clinical outcomes of patients with POLE mutated endometrioid endometrial cancerMarina Stasenko, Irina Tunnage, Charles W Ashley, et al.
Blood|August 24, 2014
Recurrent RAS and PIK3CA mutations in Erdheim-Chester diseaseJean-François Emile, Eli L Diamond, Zofia Hélias-Rodzewicz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 1, 2017
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial CarcinomaMin Yuen Teo, Richard M Bambury, Emily C Zabor, et al.
JCO Precision Oncology|September 11, 2020
Real-World Outcomes of an Automated Physician Support System for Genome-Driven OncologyJessica J Tao, Michael H Eubank, Alison M Schram, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2018
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for InterventionMaeve A Lowery, Ryan Ptashkin, Emmet Jordan, et al.
Cancer Discovery|August 11, 2018
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front MutationsAlexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, et al.
Cancer|August 19, 2020
Clinical implications of drug-induced liver injury in early-phase oncology clinical trialsSebastian P Mondaca, Dazhi Liu, Jessica R Flynn, et al.
Investigational New Drugs|March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxelLillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 22, 2022
Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIEMichele L LeNoue-Newton, Sheau-Chiann Chen, Thomas Stricker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2018
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune TherapiesJames J Harding, Subhiksha Nandakumar, Joshua Armenia, et al.
Pageof 18